The Latin America, Middle East and Africa Endometriosis Market would witness market growth of 14.0% CAGR during the forecast period (2022-2028).
A laparoscopy may be advised in specific circumstances in order to examine and surgically remove or destroy troublesome tissue. Both symptoms and fertility can be improved by doing this. Laparoscopic excision or ablation can be done by doctors. Excision involves cutting troublesome tissue away, whereas ablation involves burning the tissue with a laser or cauterizer.
In most cases dof mild or severe endometriosis, surgery relieves symptoms, although it is not always successful, and recurrence (and the requirement for additional surgical procedures) are frequent over time. Additionally, there are dangers associated with surgery that must be evaluated against any potential advantages.
In difficult situations, once all other options for therapy have been explored, a hysterectomy (removal of the fallopian tubes, uterus, and occasionally the ovaries) may be considered. Even while a hysterectomy does not always successfully treat endometriosis, it does have lower retreatment rates than other procedures, particularly when the ovaries are also removed.
The Saudi Arabian government has budgeted about $65 billion for the development of the healthcare system as part of Vision 2030. Additionally, it wants to privatize 290 hospitals and 2,300 primary health centers by 2030, increasing private sector participation from 40% to 65%. The MOH intends to establish health clusters across Saudi Arabia in order to encourage preventive and integrated care and to increase access to health service. One million individuals will be served by each cluster's integrated network of healthcare professionals. A strong healthcare industry and increasing government spending, particularly on women's health care, will serve as an opportunity for the market players in the endometriosis market.
The Brazil market dominated the LAMEA Endometriosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $35.7 million by 2028. The Argentina market is exhibiting a CAGR of 14.6% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 13.6% during (2022 - 2028).
Based on Type, the market is segmented into Superficial Peritoneal Lesion, Endometriomas, and Others. Based on Treatment, the market is segmented into Oral Contraceptives, Gonadotropin-releasing hormone (GnRH) medicines, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
A laparoscopy may be advised in specific circumstances in order to examine and surgically remove or destroy troublesome tissue. Both symptoms and fertility can be improved by doing this. Laparoscopic excision or ablation can be done by doctors. Excision involves cutting troublesome tissue away, whereas ablation involves burning the tissue with a laser or cauterizer.
In most cases dof mild or severe endometriosis, surgery relieves symptoms, although it is not always successful, and recurrence (and the requirement for additional surgical procedures) are frequent over time. Additionally, there are dangers associated with surgery that must be evaluated against any potential advantages.
In difficult situations, once all other options for therapy have been explored, a hysterectomy (removal of the fallopian tubes, uterus, and occasionally the ovaries) may be considered. Even while a hysterectomy does not always successfully treat endometriosis, it does have lower retreatment rates than other procedures, particularly when the ovaries are also removed.
The Saudi Arabian government has budgeted about $65 billion for the development of the healthcare system as part of Vision 2030. Additionally, it wants to privatize 290 hospitals and 2,300 primary health centers by 2030, increasing private sector participation from 40% to 65%. The MOH intends to establish health clusters across Saudi Arabia in order to encourage preventive and integrated care and to increase access to health service. One million individuals will be served by each cluster's integrated network of healthcare professionals. A strong healthcare industry and increasing government spending, particularly on women's health care, will serve as an opportunity for the market players in the endometriosis market.
The Brazil market dominated the LAMEA Endometriosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $35.7 million by 2028. The Argentina market is exhibiting a CAGR of 14.6% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 13.6% during (2022 - 2028).
Based on Type, the market is segmented into Superficial Peritoneal Lesion, Endometriomas, and Others. Based on Treatment, the market is segmented into Oral Contraceptives, Gonadotropin-releasing hormone (GnRH) medicines, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Superficial Peritoneal Lesion
- Endometriomas
- Others
By Treatment
- Oral Contraceptives
- Gonadotropin-releasing hormone (GnRH) medicines
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Teva Pharmaceuticals Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Sanofi S.A
- AbbVie, Inc
- AstraZeneca PLC
- Pfizer, Inc
- Merck & Co., Inc
- GlaxoSmithKline PLC
- Abbott Laboratories
- Consilient Health Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Endometriosis Market, by Type
1.4.2 LAMEA Endometriosis Market, by Treatment
1.4.3 LAMEA Endometriosis Market, by Distribution Channel
1.4.4 LAMEA Endometriosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Endometriosis Market by Type
3.1 LAMEA Superficial Peritoneal Lesion Market by Country
3.2 LAMEA Endometriomas Market by Country
3.3 LAMEA Others Market by Country
Chapter 4. LAMEA Endometriosis Market by Treatment
4.1 LAMEA Oral Contraceptives Market by Country
4.2 LAMEA Gonadotropin-releasing hormone (GnRH) medicines Market by Country
4.3 LAMEA Others Market by Country
Chapter 5. LAMEA Endometriosis Market by Distribution Channel
5.1 LAMEA Hospital Pharmacy Market by Country
5.2 LAMEA Retail Pharmacy Market by Country
5.3 LAMEA Online Pharmacy Market by Country
Chapter 6. LAMEA Endometriosis Market by Country
6.1 Brazil Endometriosis Market
6.1.1 Brazil Endometriosis Market by Type
6.1.2 Brazil Endometriosis Market by Treatment
6.1.3 Brazil Endometriosis Market by Distribution Channel
6.2 Argentina Endometriosis Market
6.2.1 Argentina Endometriosis Market by Type
6.2.2 Argentina Endometriosis Market by Treatment
6.2.3 Argentina Endometriosis Market by Distribution Channel
6.3 UAE Endometriosis Market
6.3.1 UAE Endometriosis Market by Type
6.3.2 UAE Endometriosis Market by Treatment
6.3.3 UAE Endometriosis Market by Distribution Channel
6.4 Saudi Arabia Endometriosis Market
6.4.1 Saudi Arabia Endometriosis Market by Type
6.4.2 Saudi Arabia Endometriosis Market by Treatment
6.4.3 Saudi Arabia Endometriosis Market by Distribution Channel
6.5 South Africa Endometriosis Market
6.5.1 South Africa Endometriosis Market by Type
6.5.2 South Africa Endometriosis Market by Treatment
6.5.3 South Africa Endometriosis Market by Distribution Channel
6.6 Nigeria Endometriosis Market
6.6.1 Nigeria Endometriosis Market by Type
6.6.2 Nigeria Endometriosis Market by Treatment
6.6.3 Nigeria Endometriosis Market by Distribution Channel
6.7 Rest of LAMEA Endometriosis Market
6.7.1 Rest of LAMEA Endometriosis Market by Type
6.7.2 Rest of LAMEA Endometriosis Market by Treatment
6.7.3 Rest of LAMEA Endometriosis Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.3 Sun Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Sanofi S.A.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 AbbVie, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Trials and Approvals:
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.7.5.2 Trials and Approvals:
7.8 Merck & Co., Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Trials and Approvals:
7.9 GlaxoSmithKline PLC
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Trials and Approvals:
7.9.5.2 Acquisition and Mergers:
7.10. Consilient Health Limited
7.10.1 Company Overview
Companies Mentioned
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sanofi S.A.
- AbbVie, Inc.
- AstraZeneca PLC
- Pfizer, Inc.
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Abbott Laboratories
- Consilient Health Limited
Methodology
LOADING...
